Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
21.46
Sep 23 • 3:59 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
1.93B
Enterprise Value
2.02B
Income
-
Sales
-
Book/sh
-1.07
Cash/sh
1.36
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
-
IPO
Aug 06, 2026
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
15.73
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
13.63
Current Ratio
13.63
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
No / Yes
EPS (ttm)
-
EPS next Y
-
EPS next Q
-0.44
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS past 3/5Y
- -
Sales past 3/5Y
- -
EPS Y/Y TTM
-
Sales Y/Y TTM
-
EPS Q/Q
-
Sales Q/Q
-
Insider Own
97.56%
Insider Trans
11.18%
Inst Own
-
Inst Trans
19.04%
ROA
-
ROE
-
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
-19.80%
SMA50
-20.71%
SMA200
-20.71%
Trades
Shs Outstand
90.04M
Shs Float
2.20M
52W High
32.00 -32.94%
52W Low
21.31 0.70%
Volatility
10.24% 8.81%
ATR (14)
2.39
RSI (14)
31.89
Beta
-
Rel Volume
0.00
Avg Volume
554.28K
Volume
0
Perf Week
-21.82%
Perf Month
-21.96%
Perf Quarter
-
Perf Half Y
-
Perf YTD
-28.94%
Perf Year
-
Perf 3Y
-
Perf 5Y
-
Perf 10Y
-
Prev Close
21.46
Price
21.46
Change %
0.00%
Date Action Analyst Rating Change Price Target Change
Aug-31-26Initiated TD Cowen Buy
Aug-31-26Initiated Stifel Buy $45
Aug-31-26Initiated Jefferies Buy $48
Aug-31-26Initiated Goldman Buy $48
Aug-31-26Initiated Cantor Fitzgerald Overweight $40
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
M.D.Dr. Travis Murdoch B.S.
Chief Financial OfficerMr. James Paul Rickey CPA
Chief Development OfficerMs. Michele A. Anderson
Chief Scientific OfficerMr. Marc Evanchik M.S.
VP & Head of LegalMs. Natalie Dement J.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AH Bio Fund IV, L.P.10% OwnerAug 07 '26Buy18.001,100,00019,800,00010,232,420Aug 11 05:53 PM
Chimovits ErezDirectorAug 07 '26Buy18.001,940,00034,920,00011,901,826Aug 11 05:31 PM
ORBIMED ADVISORS LLCDirectorAug 07 '26Buy18.001,940,00034,920,00011,901,826Aug 11 05:27 PM
Forbion Growth Opportunities F10% OwnerAug 07 '26Buy18.001,920,00034,560,00011,640,546Aug 07 05:25 PM
Forbion Growth Opportunities F10% OwnerAug 07 '26Buy18.001,680,00030,240,00010,185,478Aug 07 05:25 PM
Rickey James PaulChief Financial OfficerAug 07 '26Buy18.0027,777499,986520,927Aug 07 04:41 PM
Viehbacher ChristopherDirectorAug 07 '26Buy18.0083,3331,499,994609,519Aug 07 04:31 PM
Malek David IDirectorAug 07 '26Buy18.004,16674,988533,845Aug 07 04:31 PM
Anderson Michele A.Chief Development OfficerAug 07 '26Buy18.001,11119,998332,161Aug 07 04:30 PM
Murdoch TravisCEO and PresidentAug 07 '26Buy18.0083,3331,499,9942,940,670Aug 07 04:30 PM
Lubner David CharlesDirectorAug 07 '26Buy18.0055,555999,99055,555Aug 07 04:30 PM